Nogueiras-Alvarez R
Front Pharmacol. 2023; 14:1247088.
PMID: 37927590
PMC: 10625420.
DOI: 10.3389/fphar.2023.1247088.
Shin H, Lee S
BMC Med Inform Decis Mak. 2021; 21(1):159.
PMID: 34001114
PMC: 8130307.
DOI: 10.1186/s12911-021-01520-y.
van Westrhenen R, Aitchison K, Ingelman-Sundberg M, Jukic M
Front Psychiatry. 2020; 11:94.
PMID: 32226396
PMC: 7080976.
DOI: 10.3389/fpsyt.2020.00094.
Vantaku V, Amara C, Piyarathna D, Donepudi S, Ambati C, Putluri V
Carcinogenesis. 2019; 40(11):1332-1340.
PMID: 31284295
PMC: 6875901.
DOI: 10.1093/carcin/bgz128.
Wu L, Ingle T, Liu Z, Zhao-Wong A, Harris S, Thakkar S
BMC Bioinformatics. 2019; 20(Suppl 2):97.
PMID: 30871458
PMC: 6419320.
DOI: 10.1186/s12859-019-2628-5.
Characterisation of a functional rat hepatocyte spheroid model.
Kyffin J, Sharma P, Leedale J, Colley H, Murdoch C, Harding A
Toxicol In Vitro. 2018; 55:160-172.
PMID: 30578835
PMC: 6361770.
DOI: 10.1016/j.tiv.2018.12.014.
Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.
Kozyra M, Ingelman-Sundberg M, Lauschke V
Genet Med. 2016; 19(1):20-29.
PMID: 27101133
DOI: 10.1038/gim.2016.33.
Pharmacogenomics in the clinic.
Relling M, Evans W
Nature. 2015; 526(7573):343-50.
PMID: 26469045
PMC: 4711261.
DOI: 10.1038/nature15817.
Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.
Romero-Laorden N, Doger B, Hernandez M, Hernandez C, Rodriguez-Moreno J, Garcia-Donas J
Clin Transl Oncol. 2015; 18(1):1-8.
PMID: 26169213
DOI: 10.1007/s12094-015-1332-9.
LightSNiP assay is a good strategy for pharmacogenetics test.
Cheli S, Pietrantonio F, Clementi E, Falvella F
Front Pharmacol. 2015; 6:114.
PMID: 26082719
PMC: 4451335.
DOI: 10.3389/fphar.2015.00114.
Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
Takahashi H, Sai K, Saito Y, Kaniwa N, Matsumura Y, Hamaguchi T
PLoS One. 2014; 9(8):e105160.
PMID: 25127363
PMC: 4134257.
DOI: 10.1371/journal.pone.0105160.
Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning.
Liu M, Cai R, Hu Y, Matheny M, Sun J, Hu J
J Am Med Inform Assoc. 2013; 21(2):245-51.
PMID: 24334612
PMC: 3932464.
DOI: 10.1136/amiajnl-2013-002051.
Pharmacogenomics in early-phase clinical development.
Burt T, Dhillon S
Pharmacogenomics. 2013; 14(9):1085-97.
PMID: 23837482
PMC: 4551460.
DOI: 10.2217/pgs.13.81.
Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.
Trigo P, Fischer G
Clin Interv Aging. 2012; 7:1-13.
PMID: 22291468
PMC: 3267401.
DOI: 10.2147/CIA.S16677.
Current progress in pharmacogenetics.
Blakey J, Hall I
Br J Clin Pharmacol. 2011; 71(6):824-31.
PMID: 21235621
PMC: 3099369.
DOI: 10.1111/j.1365-2125.2011.03912.x.
Towards an ontological theory of substance intolerance and hypersensitivity.
Hogan W
J Biomed Inform. 2010; 44(1):26-34.
PMID: 20152933
PMC: 2888796.
DOI: 10.1016/j.jbi.2010.02.003.
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.
Hagaman J, Kinder B, Eckman M
Lung. 2010; 188(2):125-32.
PMID: 20066544
DOI: 10.1007/s00408-009-9217-8.
Expectations, validity, and reality in pharmacogenetics.
Limdi N, Veenstra D
J Clin Epidemiol. 2009; 63(9):960-9.
PMID: 19995676
PMC: 2888890.
DOI: 10.1016/j.jclinepi.2009.09.006.
Contributions of pediatrics and pediatric pathology to the body of knowledge regarding human disease.
Nezelof C, Seemayer T, Bridge J
Hum Pathol. 2009; 41(3):309-15.
PMID: 19740520
PMC: 7119320.
DOI: 10.1016/j.humpath.2009.06.017.
The future costs, risks and rewards of drug development: the economics of pharmacogenomics.
Cook J, Hunter G, Vernon J
Pharmacoeconomics. 2009; 27(5):355-63.
PMID: 19586074
DOI: 10.2165/00019053-200927050-00001.
